Literature DB >> 28498576

A critique of the "ultra-high risk" and "transition" paradigm.

Jim van Os1,2, Sinan Guloksuz1,3.   

Abstract

The transdiagnostic expression of psychotic experiences in common mental disorder (anxiety/depression/substance use disorder) is associated with a poorer prognosis, and a small minority of people may indeed develop a clinical picture that meets criteria for schizophrenia. However, it appears neither useful nor valid to observe early states of multidimensional psychopathology in young people through the "schizo"-prism, and apply misleadingly simple, unnecessary and inefficient binary concepts of "risk" and "transition". A review of the "ultra-high risk" (UHR) or "clinical high risk" (CHR) literature indicates that UHR/CHR samples are highly heterogeneous and represent individuals diagnosed with common mental disorder (anxiety/depression/substance use disorder) and a degree of psychotic experiences. Epidemiological research has shown that psychotic experiences are a (possibly non-causal) marker of the severity of multidimensional psychopathology, driving poor outcome, yet notions of "risk" and "transition" in UHR/CHR research are restrictively defined on the basis of positive psychotic phenomena alone, ignoring how baseline differences in multidimensional psychopathology may differentially impact course and outcome. The concepts of "risk" and "transition" in UHR/CHR research are measured on the same dimensional scale, yet are used to produce artificial diagnostic shifts. In fact, "transition" in UHR/CHR research occurs mainly as a function of variable sample enrichment strategies rather than the UHR/CHR "criteria" themselves. Furthermore, transition rates in UHR/CHR research are inflated as they do not exclude false positives associated with the natural fluctuation of dimensional expression of psychosis. Biological associations with "transition" thus likely represent false positive findings, as was the initial claim of strong effects of omega-3 polyunsatured fatty acids in UHR samples. A large body of UHR/CHR intervention research has focused on the questionable outcome of "transition", which shows lack of correlation with functional outcome. It may be more productive to consider the full range of person-specific psychopathology in all young individuals who seek help for mental health problems, instead of "policing" youngsters for the transdiagnostic dimension of psychosis. Instead of the relatively inefficient medical high-risk approach, a public health perspective, focusing on improved access to a low-stigma, high-hope, small scale and youth-specific environment with acceptable language and interventions may represent a more useful and efficient strategy.
© 2017 World Psychiatric Association.

Entities:  

Keywords:  Ultra-high risk; common mental disorder; psychotic experiences; public health perspective; transdiagnostic expression of psychosis; transition

Year:  2017        PMID: 28498576      PMCID: PMC5428198          DOI: 10.1002/wps.20423

Source DB:  PubMed          Journal:  World Psychiatry        ISSN: 1723-8617            Impact factor:   49.548


  59 in total

Review 1.  Prodromal schizophrenia and atypical antipsychotic treatment.

Authors:  A S Kablinger; A M Freeman
Journal:  J Nerv Ment Dis       Date:  2000-10       Impact factor: 2.254

2.  The persistence of underpowered studies in psychological research: causes, consequences, and remedies.

Authors:  Scott E Maxwell
Journal:  Psychol Methods       Date:  2004-06

3.  headspace: Australia's National Youth Mental Health Foundation--where young minds come first.

Authors:  Patrick D McGorry; Chris Tanti; Ryan Stokes; Ian B Hickie; Kate Carnell; Lyndel K Littlefield; John Moran
Journal:  Med J Aust       Date:  2007-10-01       Impact factor: 7.738

4.  Subclinical psychotic experiences and bipolar spectrum features in depression: association with outcome of psychotherapy.

Authors:  J T W Wigman; J van Os; L Abidi; M J H Huibers; J Roelofs; A Arntz; I Kelleher; F P M L Peeters
Journal:  Psychol Med       Date:  2013-05-07       Impact factor: 7.723

5.  Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk: A Meta-analytical Stratification.

Authors:  Paolo Fusar-Poli; Marco Cappucciati; Stefan Borgwardt; Scott W Woods; Jean Addington; Barnaby Nelson; Dorien H Nieman; Daniel R Stahl; Grazia Rutigliano; Anita Riecher-Rössler; Andor E Simon; Masafumi Mizuno; Tae Young Lee; Jun Soo Kwon; May M L Lam; Jesus Perez; Szabolcs Keri; Paul Amminger; Sibylle Metzler; Wolfram Kawohl; Wulf Rössler; Jimmy Lee; Javier Labad; Tim Ziermans; Suk Kyoon An; Chen-Chung Liu; Kristen A Woodberry; Amel Braham; Cheryl Corcoran; Patrick McGorry; Alison R Yung; Philip K McGuire
Journal:  JAMA Psychiatry       Date:  2016-02       Impact factor: 21.596

6.  Why are help-seeking subjects at ultra-high risk for psychosis help-seeking?

Authors:  Irina Falkenberg; Lucia Valmaggia; Majella Byrnes; Marianna Frascarelli; Ceri Jones; Matteo Rocchetti; Benjamin Straube; Steven Badger; Philip McGuire; Paolo Fusar-Poli
Journal:  Psychiatry Res       Date:  2015-05-30       Impact factor: 3.222

7.  EPA guidance on the early detection of clinical high risk states of psychoses.

Authors:  F Schultze-Lutter; C Michel; S J Schmidt; B G Schimmelmann; N P Maric; R K R Salokangas; A Riecher-Rössler; M van der Gaag; M Nordentoft; A Raballo; A Meneghelli; M Marshall; A Morrison; S Ruhrmann; J Klosterkötter
Journal:  Eur Psychiatry       Date:  2015-02-27       Impact factor: 5.361

Review 8.  [Clinical assessment of the ultra high risk of developing a a psychotic disorder; review and critical reflection].

Authors:  K Lacluyse; L van Bouwel; H Demunter; I Heleven; R van Winkel; J Peuskens; M de Hert
Journal:  Tijdschr Psychiatr       Date:  2011

9.  Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

Authors:  G Paul Amminger; Miriam R Schäfer; Konstantinos Papageorgiou; Claudia M Klier; Sue M Cotton; Susan M Harrigan; Andrew Mackinnon; Patrick D McGorry; Gregor E Berger
Journal:  Arch Gen Psychiatry       Date:  2010-02

Review 10.  Toward a world consensus on prevention of schizophrenia.

Authors:  Jim Van Os; Philippe Delespaul
Journal:  Dialogues Clin Neurosci       Date:  2005       Impact factor: 5.986

View more
  60 in total

1.  Clinical high risk for psychosis in childhood and adolescence: findings from the 2-year follow-up of the ReARMS project.

Authors:  Michele Poletti; Lorenzo Pelizza; Silvia Azzali; Federica Paterlini; Sara Garlassi; Ilaria Scazza; Luigi Rocco Chiri; Eva Gebhardt; Simona Pupo; Raballo Andrea
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-12-01       Impact factor: 4.785

2.  Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis.

Authors:  Cathy Davies; Andrea Cipriani; John P A Ioannidis; Joaquim Radua; Daniel Stahl; Umberto Provenzani; Philip McGuire; Paolo Fusar-Poli
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

3.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

4.  Beyond the "at risk mental state" concept: transitioning to transdiagnostic psychiatry.

Authors:  Patrick D McGorry; Jessica A Hartmann; Rachael Spooner; Barnaby Nelson
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

5.  Evidence That Environmental and Familial Risks for Psychosis Additively Impact a Multidimensional Subthreshold Psychosis Syndrome.

Authors:  Lotta-Katrin Pries; Sinan Guloksuz; Margreet Ten Have; Ron de Graaf; Saskia van Dorsselaer; Nicole Gunther; Christian Rauschenberg; Ulrich Reininghaus; Rajiv Radhakrishnan; Maarten Bak; Bart P F Rutten; Jim van Os
Journal:  Schizophr Bull       Date:  2018-06-06       Impact factor: 9.306

6.  Motor Issues in the Clinical High Risk Phase of Psychosis.

Authors:  Jason Schiffman
Journal:  Schizophr Bull       Date:  2017-09-01       Impact factor: 9.306

7.  Rethinking the Psychosis Threshold in Clinical High Risk.

Authors:  Andrea Raballo; Michele Poletti; William T Carpenter
Journal:  Schizophr Bull       Date:  2019-01-01       Impact factor: 9.306

8.  Relationship between duration of untreated prodromal symptoms and symptomatic and functional recovery.

Authors:  TianHong Zhang; LiHua Xu; YingYing Tang; HuiRu Cui; XiaoChen Tang; YanYan Wei; Yan Wang; Qiang Hu; ZhenYing Qian; XiaoHua Liu; ChunBo Li; JiJun Wang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-06-25       Impact factor: 5.270

9.  Dr. Strangelove, or how we learned to stop worrying and love uncertainty.

Authors:  Sinan Guloksuz; Jim van Os
Journal:  World Psychiatry       Date:  2020-10       Impact factor: 49.548

10.  Association Between Psychotic Experiences and Subsequent Suicidal Thoughts and Behaviors: A Cross-National Analysis From the World Health Organization World Mental Health Surveys.

Authors:  Evelyn J Bromet; Matthew K Nock; Sukanta Saha; Carmen C W Lim; Sergio Aguilar-Gaxiola; Ali Al-Hamzawi; Jordi Alonso; Guilherme Borges; Ronny Bruffaerts; Louisa Degenhardt; Giovanni de Girolamo; Peter de Jonge; Silvia Florescu; Oye Gureje; Josep M Haro; Yanling He; Chiyi Hu; Elie G Karam; Viviane Kovess-Masfety; Sing Lee; Jean-Pierre Lepine; Zeina Mneimneh; Fernando Navarro-Mateu; Akin Ojagbemi; José Posada-Villa; Nancy A Sampson; Kate M Scott; Juan C Stagnaro; Maria C Viana; Miguel Xavier; Ronald C Kessler; John J McGrath
Journal:  JAMA Psychiatry       Date:  2017-11-01       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.